RxDoctor Payments Data

Cynthia Wallace, MD

Family Medicine · Hermitage, TNNPI 1386615540

Payments from drug & device makers

$1,450in general payments, 2019–2025

Across 80 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$509
  • Optinose US, Inc.$162
  • AbbVie$122
  • Pfizer$102
  • Theratechnologies Inc.$102
  • Astellas Pharma US Inc$89
  • plus $365 from 10 others

What the payments were for

  • Food & beverage$1,33692%
  • Education$1148%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,450 in reported general payments places this provider in the 60th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$54,362
Medicare patients
216
Services billed
896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin103$88,714
OzempicSemaglutide77$82,498
EliquisApixaban58$57,995
JanuviaSitagliptin Phosphate43$45,928
MounjaroTirzepatide36$37,297
Tresiba Flextouch U-100Insulin Degludec54$33,865
JanumetSitagliptin Phos/Metformin Hcl33$28,512
XareltoRivaroxaban25$26,536
TradjentaLinagliptin15$17,539
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$14,760
FarxigaDapagliflozin Propanediol18$14,452
LinzessLinaclotide11$9,028
Breo ElliptaFluticasone/Vilanterol22$8,909
GlyxambiEmpagliflozin/Linagliptin13$8,051
MyrbetriqMirabegron14$7,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$509$82,49877 claims
PfizerEliquis$102$57,99558 claims
Lilly USA, LLCMounjaro$49$37,29736 claims
AbbVieLinzess, Synthroid$122$11,54845 claims
Astellas Pharma US IncMyrbetriq$89$7,84114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Hermitage

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →